New Delhi [India], December 7 (ANI): Delhi Lieutenant Governor Anil Baijal on Monday chaired a meeting with Principal Secretary (Health) and Directorate General of Health Services (DGHS) and additional director of Serum Institute of India (SII) to review preparedness for COVID-19 vaccination
New Delhi [India], December 7 (ANI): After Serum Institute India (SII) applied for the emergency use authorisation of its coronavirus vaccine "COVISHIELD", its CEO Adar Poonawala expressed gratitude to Prime Minister Narendra Modi and the central government for the support.
New Delhi [India], December 7 (ANI): The Serum Institute of India (SII) has applied to the Drugs Controller General of India (DCGI) seeking emergency use authorisation for its COVID-19 vaccine "Covishield" in the country.
New Delhi [India], December 1 (ANI): Stressing that the Covishield vaccine is "safe and immunogenic", the Serum Institute of India (SII) on Tuesday said the incident with the Chennai volunteer was in no way induced by the vaccine as "requisite regulatory and ethical processes and guideline"
New Delhi [India], November 29 (ANI): After a Chennai-based man claimed that he suffered neurological and psychological side effects after taking a shot of COVID-19 vaccine candidate Covishield during the human trial, being conducted by Serum Institute of India's (SII), the Pune-based com
Pune (Maharashtra) [India], November 28 (ANI): Hours after Prime Minister Narendra Modi visited Pune-based Serum Institute of India (SII), its Chief Executive Officer Adar Poonawalla said that he was amazed by the Prime Minister's knowledge about vaccines and vaccine production.
New Delhi [India], November 28 (ANI): After Prime Minister Narendra Modi visited the company's pandemic level facility in Pune, Serum Institute of India's (SII), Chief Executive Officer (CEO) Adar Poonawalla on Saturday said that indications suggest that the central government may purchase 3
Pune (Maharashtra) [India], November 27 (ANI): Preparations are underway at Serum Institute of India (SII) where Prime Minister Narendra Modi is expected to visit on November 28 to review the COVID-19 vaccine production and its distribution mechanisms.
New Delhi [India], November 25 (ANI): A day after Serum Institute of India (SII) Chief Executive Officer Adar Poonawalla asserted that its "soon to be widely available COVID-19 vaccine will offer protection up to 90 per cent in one type of dosage regime", Council of Scientific and Industrial
New Delhi [India], November 23 (ANI): Serum Institute of India (SII), CEO, Adar Poonawalla on Monday said that he is delighted to hear that Covidshield, soon to be widely available COVID-19 vaccine, will offer protection up to 90 per cent in one dosage regime and 62 per cent in another.
New Delhi [India], November 19 (ANI): Major drug marker Serum of Institute of India (SII) on Thursday said that the coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years
New Delhi [India], November 12 (ANI): The Serum Institute of India (SII) and Indian Council of Medical Research (ICMR) have announced the completion of enrolment of phase 3 clinical trials for COVISHIELD in India.